share_log

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar將在第36屆派傑投資醫療保健會議上發表演講
GlobeNewswire ·  12/03 21:00

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.

威爾梅特,伊利諾伊州,2024年12月3日(環球通訊社) -- monopar therapeutics公司(納斯達克:MNPR)是一家處於臨床階段的生物技術公司,專注於爲有待滿足的醫療需求的患者開發創新治療方案,今天宣佈,首席執行官Chandler Robinson醫學博士將參加第36屆派傑投資醫療會議的一場爐邊談話,並進行一對一會議。

Presentation Details:

演示說明:

Date: December 5, 2024
Time: 10:30-10:55 am Eastern Time
Location: Lotte New York Palace, NY, NY

日期:2024年12月5日
時間:東部時間上午10:30-10:55
地點:紐約洛特宮,紐約,紐約

About Monopar Therapeutics Inc.

關於Monopar Therapeutics Inc。

Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: .

Monopar therapeutics是一家臨床階段的生物技術公司,擁有針對威爾遜病的後期ALXN-1840,以及包括早期階段MNPR-101-Zr用於影像學檢查的愛文思控股癌症治療項目,以及早期階段MNPR-101-Lu和晚期臨床前階段MNPR-101-Ac225用於治療晚期癌症的項目。有關更多信息,請訪問: .

CONTACT:

聯繫方式:

Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com

Monopar Therapeutics Inc.
投資者關係
Karthik Radhakrishnan
首席財務官
karthik@monopartx.com

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

請關注monopar的社交媒體獲取最新動態:
推特:@MonoparTx 領英:Monopar Therapeutics


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論